Bengaluru, July 9 -- One of India's most trusted pharmaceutical names has just taken a major step to deepen its international presence. At a time when biosimilars are gaining global momentum, this Mumbai headquartered drugmaker has inked a high-potential deal that could boost its long-term revenue and presence across key global markets.

The company in focus is Lupin Limited, with a market capitalization of Rs. 88,071 crore. The stock opened today at Rs. 1,933.40, slightly above its previous close of Rs. 1,922.10, and touched an intraday high of Rs. 1,965.50, reflecting a 2.26 percent gain, following the announcement of this strategic partnership.

What's the news? Lupin has entered into a License and Supply Agreement with Zentiva, k.s., ...